A Study to Evaluate Platelet Rich Plasma (PRP) for Facial and Hand Skin Rejuvenation

Overview

Información sobre este estudio

The overall goal of this study is to develop regenerative cell therapy for use in female patients with aging skin. The primary objective of this proposal is to conduct a pilot study on the efficacy and safety of using platelet rich plasma (PRP) to treat this condition in females.

Elegibilidad para la participación

Los requisitos de elegibilidad de los participantes incluyen la edad, el sexo, el tipo y el estadio de la enfermedad, y los problemas de salud o tratamientos previos. Las pautas difieren de un estudio a otro e identifican quiénes pueden o no pueden participar. No hay garantía de que cada persona elegible que desee participar en un ensayo se inscribirá. Comunícate con el equipo del estudio para analizar la elegibilidad del estudio y la posible participación.

Inclusion Criteria

  • Only female patients are eligible.
  • Patients must be 45 years of age or older.
  • Patients must have signs of skin aging on face (wrinkles, rough texture, skin atrophy and skin laxity) and hands (loss of fat tissue and visibility of veins and tendons).
  • Patients must have been on stable birth control for the past 6 months if able to conceive
  • Patients are able and willing to provide written informed consent after the study is fully explained.

Exclusion Criteria

  • Patients with clinically abnormal platelet count]\, serum chemistry, or screening laboratory results as reviewed by the Principal Investigator.
  • Patients who have had any cosmetic procedures meant to address skin aging of face and hands 3 months prior to enrollment.
  • Patients who have had resurfacing laser on face or hands within one year prior to enrollment.
  • Patients taking anti-rheumatic disease medication (including methotrexate or other anti-metabolites) within the 3 months prior to study entry.
  • Patients who are pregnant or currently breast-feeding.
  • Patients with systemic, rheumatic, or inflammatory disease or who are immunosuppressed.
  • Patients with ongoing infectious disease, including HIV and hepatitis.
  • Patients with history of significant cardiovascular, renal, hepatic, endocrine disease, cancer, or diabetes.
  • Patients participating in a study of an experimental drug or medical device within 30 days of study entry.
  • Patients with history of platelet disorders, bone marrow aplasia, sepsis, or cancer.
  • Patients taking anti-aggregating therapy.
  • Patients on anticoagulant therapy.
  • Patients with history of keloid formation.
  • Patients with uncontrolled diabetes.
  • Patients with active skin disease or skin infection on the intended treatment areas, at baseline.

Sedes participantes de Mayo Clinic

Los estatus de los estudios cambian con frecuencia. Comunícate con el equipo del estudio para obtener la información más actualizada acerca de la posibilidad de participar.

Sede de Mayo Clinic Estatus Contacto

Jacksonville, Fla.

Investigador principal de Mayo Clinic

Alison Bruce, M.B., Ch.B.

Cerrado para la inscripción

Contact information:

Ena Whitelaw CCRP

Whitelaw.Ena@mayo.edu

More information

Publicaciones

Publications are currently not available
.
CLS-20426330

Mayo Clinic Footer